DE3650492T2 - Therapeutische Nukleoside - Google Patents

Therapeutische Nukleoside

Info

Publication number
DE3650492T2
DE3650492T2 DE3650492T DE3650492T DE3650492T2 DE 3650492 T2 DE3650492 T2 DE 3650492T2 DE 3650492 T DE3650492 T DE 3650492T DE 3650492 T DE3650492 T DE 3650492T DE 3650492 T2 DE3650492 T2 DE 3650492T2
Authority
DE
Germany
Prior art keywords
htlv
azido
against human
animal
therapeutic nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3650492T
Other languages
English (en)
Other versions
DE3650492D1 (de
Inventor
Janet Litster Rideout
David Walter Barry
Sandra Nusinoff Lehrman
Clair Martha Heider St
Phillip Allen Furman
Iii Lowrie Miller Beacham
Harry Sidney Leblanc
George Andrew Freeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858506869A external-priority patent/GB8506869D0/en
Priority claimed from GB858506868A external-priority patent/GB8506868D0/en
Priority claimed from GB858511774A external-priority patent/GB8511774D0/en
Priority claimed from GB858511775A external-priority patent/GB8511775D0/en
Priority claimed from GB858523881A external-priority patent/GB8523881D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE3650492D1 publication Critical patent/DE3650492D1/de
Application granted granted Critical
Publication of DE3650492T2 publication Critical patent/DE3650492T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
DE3650492T 1985-03-16 1986-03-14 Therapeutische Nukleoside Expired - Fee Related DE3650492T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858506869A GB8506869D0 (en) 1985-03-16 1985-03-16 Antiviral compound
GB858506868A GB8506868D0 (en) 1985-03-16 1985-03-16 Antibacterial compound
GB858511774A GB8511774D0 (en) 1985-05-09 1985-05-09 Antiviral compounds
GB858511775A GB8511775D0 (en) 1985-05-09 1985-05-09 Antibacterial compounds
GB858523881A GB8523881D0 (en) 1985-09-27 1985-09-27 Antiviral compounds

Publications (2)

Publication Number Publication Date
DE3650492D1 DE3650492D1 (de) 1996-04-11
DE3650492T2 true DE3650492T2 (de) 1996-10-31

Family

ID=27516577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650492T Expired - Fee Related DE3650492T2 (de) 1985-03-16 1986-03-14 Therapeutische Nukleoside

Country Status (9)

Country Link
EP (1) EP0199451B1 (de)
JP (1) JPH0723314B2 (de)
AT (1) ATE135011T1 (de)
AU (1) AU578809B2 (de)
CA (1) CA1285935C (de)
DE (1) DE3650492T2 (de)
DK (1) DK166805B1 (de)
IE (1) IE73219B1 (de)
MY (1) MY104069A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
KR860006987A (ko) * 1985-03-16 1986-10-06 엠. 피. 잭슨 항 비루스성 뉴클레오시드의 제조방법 및 이것을 함유한 약학적 제형 제조방법
MC1742A1 (fr) * 1985-03-16 1987-02-26 Wellcome Found Procede pour preparer un derive de 3'-azido-3'desoxythymigline et procede pour preparer une formulation pharmaceutique le contenant
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
EP0332626A1 (de) * 1986-11-21 1989-09-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Zubereitungen zur behandlung viraler infektionen bei menschen
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
JPS63290894A (ja) * 1987-03-16 1988-11-28 ザ　ウエルカム　フアウンデーション　リミテッド 治療用ヌクレオシド
EP0286825A3 (de) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von 3'-fluro-3'-deoxythymidine zur Herstellung von medicamenten zur Behandlung von Viruskrankheiten
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
EP0516186A3 (en) * 1987-04-16 1993-01-13 Medivir Aktiebolag Nucleosides and nucleoside analogues, pharmaceutical composition and processes for the preparation of the compounds
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5215970A (en) * 1987-04-16 1993-06-01 Medivir Ab Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US4804651A (en) * 1987-06-09 1989-02-14 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of psoriasis
YU110888A (en) * 1987-06-10 1989-08-31 Wellcome Found Process for obtaining timine derivatives
USRE33887E (en) * 1987-06-22 1992-04-14 Hoffmann-La Roche Inc. Anti-retroviral compounds
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
SU1548182A1 (ru) * 1987-12-29 1990-03-07 Институт молекулярной биологии АН СССР 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
FR2640267B2 (fr) * 1988-01-19 1992-02-14 Univ Paris Curie Procede de synthese de l'azido-3(prime)-desoxy-3(prime)-thymidine et analogues
FR2626001B1 (fr) * 1988-01-19 1991-11-08 Univ Paris Curie Procede de synthese de l'azido-3ÿi1ÿ.-desoxy-3ÿi1ÿ.-thymidine et analogues
US4921950A (en) * 1988-06-09 1990-05-01 Burroughs Wellcome Co. Preparation of 3'azido-3-'-deoxythymidine
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
FR2635778A1 (fr) * 1988-08-26 1990-03-02 Ire Celltarg Sa Nouveaux derives de la 3(prime) azido-3(prime) deoxythymidine (azt) actifs contre le virus hiv du sida
IE980216A1 (en) * 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
HU205089B (en) * 1989-05-31 1992-03-30 Biogal Gyogyszergyar Process for producing new thymine derivatives and pharmaceutical compositions comprising same
FR2653771B1 (fr) * 1989-10-27 1994-09-23 Univ Paris Curie Procede de preparation de l'azt (azido-3'-desoxy-3'-thymidine) et de composes apparentes.
FR2656867A1 (fr) * 1990-01-09 1991-07-12 Centre Nat Rech Scient Nouveau derives de la thymidine, leur preparation et les compositions qui les contiennent.
FR2668153B1 (fr) * 1990-10-22 1995-03-31 Pasteur Merieux Serums Vacc Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
US5451671A (en) * 1992-07-27 1995-09-19 Ajinomoto Co., Inc. Method of purifying 2',3'-dideoxynucleosides
EP0641352B1 (de) * 1993-02-23 1997-06-04 City Of Hope 4-ethoxy-5-fluor-2'-deoxyuridine
DE69533856T2 (de) * 1994-10-24 2005-12-08 Genencor International, Inc., Palo Alto L-pyranosyl-nukleoside
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2134292A1 (en) * 1971-04-30 1972-12-08 Inst Nat Sante Rech Med Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

Also Published As

Publication number Publication date
DK118286A (da) 1986-09-17
DK166805B1 (da) 1993-07-19
EP0199451B1 (de) 1996-03-06
AU578809B2 (en) 1988-11-03
DE3650492D1 (de) 1996-04-11
EP0199451A2 (de) 1986-10-29
AU5475786A (en) 1986-09-18
CA1285935C (en) 1991-07-09
MY104069A (en) 1993-11-30
ATE135011T1 (de) 1996-03-15
JPS61257926A (ja) 1986-11-15
IE860676L (en) 1986-09-16
EP0199451A3 (en) 1990-09-05
IE73219B1 (en) 1997-05-07
JPH0723314B2 (ja) 1995-03-15
DK118286D0 (da) 1986-03-14

Similar Documents

Publication Publication Date Title
DE3650492T2 (de) Therapeutische Nukleoside
MY102693A (en) Antiviral nucleosides
DK224286A (da) 2',3'-dideoxy-nucleosider
DE69635656D1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
RU93045710A (ru) Противовирусная нуклеозидная композиция, способ ее получения и способ лечения
FI20001231A (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ES2052732T3 (es) 2',3'-didesoxi-3'-fluorotimidina y compuestos afines para el tratamiento de infecciones por adenovirus.
NO923721D0 (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
DE68912020D1 (de) N-2,3-Butadienyl-tri-aminoalkanderivate.
FI894139A (fi) Antibiotiska sulfonylaminokarbonyl aktiverade b-laktamer.
ATE147746T1 (de) Derivate von fluorphosphonat-nukleotiden
DE68929321T2 (de) Therapeutische Anwendungen von 2',5'-Oligoadenylat-Derivaten
ATE96845T1 (de) Teicoplaninaehnliche derivate.
FI893932A (fi) Expression av funktionella homologa och heterologa proteiner pao yttre membran av e.coli och andra gram-negativa bakterier.
FR2496663B1 (fr) Nouveaux derives de naphtyridine-1,8 utiles notamment comme medicaments antibacteriens
ITRM920603A0 (it) La sequenza dell'inserto cprl3, parte del gene della proteina della oociste di cryptosporidium (cowp), e derivati utili per la diagnosi dell'infezione da cryptosporidium
FI933165A (fi) Nya fosfolipidderivat
MA21651A1 (fr) Nouveaux derives de la methoxycarbonyl-2n,n'-di- (trimethoxybenzoyle) piperazine, ainsi que leur procede de preparation .
ES2053434T3 (es) Derivados de arginina y agmatina para el tratamiento de la infecciones protozoarias.
MX9203634A (es) Derivados de pirocatecol 3,5-disubstituidos.
IT8721454A0 (it) Composti ad attivita' antivirale, procedimento per la loro preparazione e relative composizioni farmaceutiche.
ATA265687A (de) 1,3,5-trithianderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee